Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2012

View Archived Issues

Amgen presents novel TRPM8 channel antagonist

Novel antidiabetic drug Subetta evaluated in animal model

Novel deuterated analogues of mibefradil show reduced propensity for CYP3A4-mediated interactions

Studies support the use of tofogliflozin in patients with renal impairment

BioCryst Pharmaceuticals enters merger agreement

Starpharma completes recruitment in phase III VivaGel trials

Biogen Idec notified of PDUFA date extension

FDA accepts quadrivalent influenza vaccine sBLA for review

First use of CardioCel tissue patch to repair congenital heart defects

Progen Pharmaceuticals reports phase II data for PI-88 in melanoma

ProNoxis researchers synthesize new ROS production enhancers

Advinus Therapeutics presents new JAK inhibitors

Researchers describe activity of TAC-302

Trevena divulges new opioid receptor ligands

FDA committee votes to recommend approval of Kynamro

New IL-7A proteins prepared at the University of Central Florida

Phase II and III studies of bardoxolone methyl suspended

Hyundai Pharmaceutical patents new 11-beta-HSD1 inhibitors

Japanese Foundation for Cancer Research presents new antibodies

Quantum Genomics reports promising results from phase Ia trial of new antihypertensive agent

Curis achieves first milestones in CUDC-907 development

Ipsen to conduct phase II study of tasquinimod in multiple tumor types

EMA committee issues opinion on Qsiva

Pfenex receives NIH contract to develop dry formulation of rPA-based anthrax vaccine

Redx Pharma receives support to launch center for antiviral and antibacterial drugs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...